Clinical Trial Update: PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes [Phase 1, Phase 2]

View source ↗

Summary

This is a Phase 1/2 PK and efficacy bridging study of ASTX727 in Chinese patients with myelodysplastic syndromes, sponsored by Otsuka Beijing Research Institute…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• ASTX727 (cedazuridine/decitabine)

Snippet

Sponsor: Otsuka Beijing Research Institute | Conditions: Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING